>Influenza Virus Research Reagents
Influenza Virus Research Reagents H7N9 Protein & Antibody New !
300+ influenza research reagents
- 170+ proteins, 80+ antibodies, 8 ELISA kits, 50+ gene cDNA clones
- Cover 80 strains of influenza A H1-H16 and influenza B
- Research tools for HA, NA, NP, M1, NS1, and NS2
1st develop flu 2009 testing kit
- Produced H1N1 HA from the 2009 swine influenza within 30-days of public release of the virus gene sequence
- First in developing Mabs to the 2009 H1N1 virus
- World's first H1N1 (Swine Flu 2009) HA ELISA kit: SEK001
Best influenza antibodies
- Highly specific 2009 swine flu HA antibodies, no cross-reactivity to seasonal flu strains
- High-affinity rabbit Mabs: detection limit 0.00245 ng/well
- Wide applications: WB, ELISA, FCM, inhibition
Highly active influenza NA
- Active NA of influenza A H1N1, H5N1, H3N2, H9N2
- Recombinant H1N1 NA (11058-V07B) is lyophilized and highly active
Locate influenza research reagents of interest through four ways:
Influenza B strains
|H1N1 HA||H1N2 HA||H1N3 HA||H2N2 HA||H3N2 HA|
|H4N4 HA||H4N6 HA||H4N8 HA||H5N1 HA||H5N2 HA|
|H5N3 HA||H5N8 HA||H6N1 HA||H6N4 HA||H7N7 HA|
|H8N4 HA||H9N2 HA||H10N3 HA||H10N9 HA||H11N2 HA|
|H11N9 HA||H12N1 HA||H12N5 HA||H13N8 HA||H15N8 HA|
|H16N3 HA||Influenza B HA||H7N9 HA NEW|
|H1N1-NA||H5N1-NA||H3N2-NA||H7N9 NA NEW||H9N2-NA|
|H1N1-HA ELISA Kit||H5N1-HA ELISA Kit||H3N2-HA ELISA Kit||H7N7-HA ELISA Kit|
|Influenza B-HA ELISA Kit|
- Pandemic Influenza Virus: Hemagglutinin & Antibodies
- - 2009 Influenza Pandemic (H1N1 Swine Flu)
- - 1968 Influenza Pandemic (Hong Kong Flu)
- - 1957 Influenza Pandemic (Asian Flu)
- - 1918 influenza pandemic (Spanish Flu)
- - H5N1 Influenza Pandemic Threat (Avian Flu)
- - H7N7 Influenza Pandemic Threat
- - H9N2 Influenza Pandemic Threat
4. Tools for seasonal influenza subtypes
- Wide selection: Rabbit MAbs, mouse MAbs, rabbit PAbs, labeled antibodies, etc.
- Higher affinity, lower detection limit (as low as 0.02 ng / well in ELISA detection) compared to an US leading brand
- Proteins, instead of peptides, used as immunogens
State-of-the-art monoclonal antibody development platforms
Influenza virus research
Influenza (flu) is a respiratory infection in mammals and birds. It is caused by an RNA virus in the family Orthomyxoviridae. The virus is divided into three main types (Influenza A, Influenza B, and Influenza C), which are distinguished by differences in two major internal proteins (hemagglutinin (HA) and neuraminidase (NA)). Influenza virus type A is found in a wide variety of bird and mammal species and can undergo major shifts in immunological properties. Influenza virus type B is largely confined to humans and is an important cause of morbidity. Little is known about Influenza virus type C, which is not an important source of morbidity.
Influenza A is further divided into subtypes based on differences in the membrane proteins hemagglutinin (HA) and neuraminidase (NA), which are the most important targets for the immune system. The notation HhNn is used to refer to the subtype comprising the hth discovered Hemagglutinin (HA) protein and the nth discovered neuraminidase (NA) protein. The influenza viral Hemagglutinin (HA) protein is a homo trimer with a receptor binding pocket on the globular head of each monomer, and the influenza viral neuraminidase (NA) protein is a tetramer with an enzyme active site on the head of each monomer. Subtypes are further divided into strains; each genetically distinct virus isolate is usually considered to be a separate strain.
Influenza viruses that are known to infect human include the following sub-types. H1N1 virus that caused "Spanish Flu" (A/BrevigMission/1/1918(H1N1)) and seasonal flu (A/Brisbane/59/2007(H1N1), A/New Caledonia/20/1999(H1N1), and A/Solomon Islands/3/2006 (H1N1)) and a reassorted virus (A/California/04/2009(H1N1)) that caused the 2009 swine flu outbreak; H2N2 virus that caused the "Asian Flu"; H3N2 virus that caused the "Hong Kong Flu"; H5N1 "The Bird Flu" virus (A/Anhui/1/2005 (H5N1), A/Vietnam/1203/2004, A/Vietnam/1194/2004 (H5N1), A/bar-headed goose/Qinghai/14/2008 (H5N1), A/turkey/1/2005 (H5N1), A/Indonesia/5/2005 (H5N1)) that was the world's major influenza pandemic threat until the Swine Flu Pandemic of 2009; H7N7 virus that has unusual zoonotic potential; H1N2 is currently endemic in humans and pigs; and H9N2, H7N2, H7N3, H10N7 viruses.
Influenza research involves investigating molecular virology, pathogenesis, host immune responses, genomics, and epidemiology regarding influenza. The main goal of influenza research is to develop influenza countermeasures such as vaccines, therapies and diagnostic tools. Influenza virus vaccination is an effective approach to control influenza virus infection and pandemic spread of the virus. Each seasonal influenza vaccine contains hemagglutinin (HA) and neuraminidase antigen from three influenza subtype viruses-one subtype Influenza A H3N2 virus, one regular seasonal Influenza A H1N1 virus (not the 2009 H1N1 virus), and one Influenza B virus. Because of the influenza virus continues to mutate (antigen minor drifting or antigen major shifting) over time, the viruses in the vaccine change each year based on international surveillance and scientists' estimations about which types and strains of viruses will circulate in a given year. About 2 weeks after vaccination of the influenza viral antigen, antibodies that provide protection against influenza virus infection develop in the body.
Protection mechanism of influenza vaccine is well established to be neutralizing antibody (polyclonal human antibody) raised against influenza viral protein antigen such as the hemagglutinin (HA ) and neuraminidase (NA) protein antigen. Neutralizing antibody can block virus binding to host cells, block viral entry into host cells, and kill infected host cells. Recombinant monoclonal antibody (Mab, mouse monoclonal antibody, rabbit monoclonal antibody, chimeric monoclonal antibody, humanized monoclonal antibody) raised against the hemagglutinin (HA ) antigen or cloned from human B-cells (human monoclonal antibody) have shown to be promising anti-influenza infection product candidates.
At present, there are only three licensed anti-Influenza drugs namely Relenza (Zanamivir - ZMV), Tamiflu (Oseltamivir - OTV) and Amantadine/Rimantadine. The latter targets the M2 ion channel whereas the other compounds target neuraminidase (NA) and were designed through structure-based enzyme inhibitor programmes. Neuraminidase promotes influenza virus release from infected cells and facilitates virus spread within the respiratory tract. The neuraminidase inhibitors interfere with the release of progeny influenza virus from infected host cells, thereby halts the spread of infection in the respiratory tract. The influenza neuraminidase inhibitors are associated with very little toxicity and are far less likely to promote the development of drug-resistant influenza. In addition, the neuraminidase inhibitors are effective against all neuraminidase subtypes and, therefore, against all strains of influenza, a key point in epidemic and pandemic preparedness. Because of a broader antiviral spectrum, better tolerance, and less potential for emergence of resistance than is seen with the M2 inhibitors, the neuraminidase inhibitors represent an important advance in the treatment of influenza.